Nacubactam has some intrinsic antibacterial activity as a consequence of PBP2 inhibition [141]. It appears to acquire significant in vivo activity against AmpC-overproducing and Klebsiella pneumoniae isolates from all continents, Whilst the susceptibility rates for your comparator agents have been generally reduced in Europe than another geographic areas (Table 4). https://cashvaehl.csublogs.com/34472727/the-ultimate-guide-to-arq-531